top of page

FDA grants Breakthrough Therapy Designation to Opdivo in SCCHN

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Bristol-Myers Squibb’s Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page